Pdi Inc (PDII) 0.53 $PDII
Onconova Therapeutics, Inc. Announces Appointment of Jack E. Stover to Board of Directors
GlobeNewswire - Mon May 23, 7:01AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Jack E. Stover has been appointed to its Board of Directors.
ONTX: 6.28 (-0.59), IDXG: 0.34 (+0.02), PDII: 0.53 (-0.02)
PDI Completes Sale of Its Commercial Services Business to Publicis Healthcare Communications Group
PR Newswire - Tue Dec 22, 12:07PM CST
PDI, Inc. (Nasdaq: PDII) announced the closing of the definitive asset purchase agreement under which Publicis Healthcare Communications Group has acquired PDI's Commercial Services business (CSO) for the initial upfront cash payment of $25.5 million. The total gross cash proceeds are approximately $28.5 million, which includes the upfront cash payment as well as a closing working capital payment. The agreement was previously announced on November 2nd, 2015 and on December 22, 2015 the transaction was approved by a majority of the PDI stockholders. Today, PDI changed its corporate name to Interpace Diagnostics Group (Interpace), Inc. and it will begin trading under the trading symbol IDXG on NASDAQ on December 23, 2015. The Company is using the proceeds from the transaction to pay off its existing senior commercial debt and for ongoing working capital to drive the growth of its molecular diagnostics operations.
PDII: 0.53 (-0.02)
PDI, Inc. Implements Leadership Transition
PR Newswire - Tue Dec 22, 5:00AM CST
PDI, Inc.(Nasdaq: PDII) today reported that as the Company transitions to focusing solely on its molecular diagnostics operations, Nancy Lurker has resigned as President, CEO and a member of the Company's board of directors effective immediately upon the expected closing of the proposed sale of the Company's Commercial Services Business. She has been succeeded on an interim basis by Jack E. Stover, previously Chairman of the Company's Audit Committee, while a search for a permanent chief executive officer has been initiated.
PDII: 0.53 (-0.02)
PDI, Inc. Implements Broad Based Efficiencies To Position Interpace Diagnostics For Long Term Growth
PR Newswire - Mon Dec 07, 8:12AM CST
PDI, Inc. (NASDAQ: PDII) implemented a broad based program to maximize efficiencies as the Company expects to close its sale of the CSO business by the end of 2015 and focus its resources on growing its Interpace Diagnostics business. As previously disclosed, upon closing of the proposed sale of the CSO business, PDI will change its name to Interpace Diagnostics Group, Inc.
PDII: 0.53 (-0.02)
PDI, Inc. Sets Special Stockholder Meeting Date of December 22, 2015 to Vote on Sale of Commercial Services (CSO) Business to Publicis Groupe
PR Newswire - Mon Nov 23, 3:20PM CST
PDI, Inc. (Nasdaq: PDII) today reported that its Board of Directors has set December 22, 2015 as the date of the special meeting of its stockholders to vote on the proposed sale of its Commercial Services business (CSO) to Publicis Healthcare Communications Group (PHCG), part of Publicis Groupe [Euronext Paris: FR0000130577, CAC40] pursuant to an asset purchase agreement entered into on October 30, 2015. The special meeting of stockholders will be held at PDI's corporate headquarters located at Morris Corporate Center One, 300 Interpace Parkway, Building A, Parsippany, NJ 07054. Stockholders of record as of November 20, 2015 are entitled to notice of and to vote at the special meeting.
PDII: 0.53 (-0.02)
Interpace Diagnostics Announces Continued Medicare Coverage for PancraGEN(TM) Pancreatic Cyst Risk Classifier Test
PR Newswire - Mon Nov 16, 5:30AM CST
PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, announced today that Novitas Solutions, Inc., the Medicare Administrative Contractor (MAC) for Interpace Diagnostics, has updated its Local Coverage Determination (LCD) for PancraGEN(TM). The PancraGEN test utilizes the PathFinderTG® platform. The original coverage issued on November 5th, 2010 provided "Coverage with Appropriateness Development," which required the Company to routinely present updated data to further validate the test's effectiveness. The new policy no longer includes this condition for coverage and is effective December 31st, 2015 and ensures continued coverage of PancraGEN for Medicare eligible patients.
PDII: 0.53 (-0.02)
PDI Reports 2015 Third Quarter and Nine Months Financial Results
PR Newswire - Thu Nov 12, 3:01PM CST
PDI, Inc. (NASDAQ: PDII) today reported financial and operational results for the third quarter and nine months ended September 30, 2015.
PDII: 0.53 (-0.02)
PDI Inc. to Report 2015 Third Quarter Financial Results
PR Newswire - Thu Nov 05, 12:04PM CST
PDI, Inc. (Nasdaq: PDII) today announced it will report financial results for its 2015 third quarter ended September 30, 2015, on Thursday, November 12, 2015, after the close of the U.S. financial markets.
PDII: 0.53 (-0.02)
PDI Enters Definitive Agreement to Sell Its Commercial Services Business to Publicis Healthcare Communications Group
PR Newswire - Mon Nov 02, 1:00AM CST
PDI, Inc. (Nasdaq: PDII) and Publicis Healthcare Communications Group (PHCG), part of Publicis Groupe [Euronext Paris: FR0000130577, CAC40], have entered into a definitive asset purchase agreement under which PHCG will acquire PDI's Commercial Services business (CSO) for an initial cash payment at closing of up to approximately $33 million, $7 million of which is contingent upon securing certain CSO client commitments, plus an earnout payment based upon 2016 CSO revenue. While there are no assurances that any earnout payment will be achieved, PDI expects the earnout payment to range from $5 million to $15 million if certain CSO client commitments are obtained. If earned, the earnout payment will be payable in April 2017. This transaction, which has been unanimously approved by the board of directors of both companies, is subject to PDI's stockholder approval and customary closing conditions. Stockholders representing approximately 46% percent of PDI's outstanding shares have agreed, subject to certain conditions, to vote in favor of the transaction.
PDII: 0.53 (-0.02)
Interpace Diagnostics Announces New Data Further Validating the Power of the Combination of its Molecular Diagnostic Thyroid Tests ThyGenX® and ThyraMIR(TM)
PR Newswire - Wed Oct 21, 8:01AM CDT
PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, announced new data presented at the 15th International Thyroid Congress and 85th Annual Meeting of the American Thyroid Association (ITC/ATA) this week in Lake Buena Vista, Florida (www.ITC2015.thyroid.org) demonstrating that combination testing by ThyGenX®, oncogene panel, and ThyraMIR(TM), microRNA classifier, has been analytically validated on fixed nodule specimens including Formalin Fixed Paraffin Embedded (FFPE) samples, cytology slides and Thin Prep slides, in addition to the current molecular analysis of fine needle aspirations (FNAs). The ability to analyze fixed thyroid samples now allows for molecular evaluation of older archived samples. An additional benefit is that this expanded menu of molecular testing on cytology slides and Thin Prep sample types can potentially eliminate the need for a second needle pass during patient biopsy.
PDII: 0.53 (-0.02)
Interpace Diagnostics Announces New Analyses Showing Positive Impact of PancraGEN(TM) in the Clinical Management of Pancreatic Cysts
PR Newswire - Mon Oct 19, 7:00AM CDT
PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, announced data that were presented in two posters during the American College of Gastroenterology (ACG) Annual Scientific Meeting and Postgraduate Course, October 16-21, 2015, Honolulu, Hawaii. The data presented demonstrated that PancraGEN(TM) can improve the detection of malignant or highly aggressive pancreatic cysts over current guideline criteria in patient management.
PDII: 0.53 (-0.02)
PDI Loss Narrower than Expected in Q2, Revenues Surpass
Zacks Equity Research - Zacks Investment Research - Fri Aug 14, 9:10AM CDT
PDI, Inc. (PDII) incurred operating loss of 44 cents in the second quarter of 2015, narrower than the Zacks Consensus Estimate of loss of 46 cents.
SFUN: 4.79 (+0.06), PDII: 0.53 (-0.02), CORE: 89.50 (-2.50), CATM: 40.27 (-0.85)
Interpace Diagnostics Announces Additional Coverage in Top Managed Care Health Plans for Their Thyroid and Pancreas Molecular Diagnostic Tests
PR Newswire - Thu Aug 13, 3:27PM CDT
PDI, Inc. (NASDAQ: PDII) subsidiary Interpace Diagnostics announced today that both the ThyGenX(TM) Thyroid Oncogene Panel and ThyraMIR(TM) Thyroid miRNA Classifier, its molecular diagnostic tests for indeterminate thyroid nodules, are now covered by one of the largest independent Blue Cross Blue Shield plans that insures 3.3 million lives. This medical policy update, covering both ThyGenX and ThyraMIR, represents the first large commercial plan to cover ThyraMIR, a novel microRNA gene expression classifier launched earlier this year. Furthermore, it follows the recent announcement of coverage by Aetna for ThyGenX, Interpace Diagnostics' genetic mutation panel used to improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis of thyroid cancer. The combination of all plans, including Medicare coverage of ThyGenX, represents a total of 80 million covered lives for Interpace Diagnostics' molecular thyroid diagnostic tests.
PDII: 0.53 (-0.02)
PDI Reports 2015 Second Quarter and Six Months Financial Results
PR Newswire - Thu Aug 13, 3:01PM CDT
PDI, Inc. (NASDAQ: PDII) today reported financial and operational results for the second quarter and six months ended June 30, 2015.
PDII: 0.53 (-0.02)
PDI Inc. to Report 2015 Second Quarter Financial Results
PR Newswire - Tue Aug 04, 6:30AM CDT
PDI, Inc. (Nasdaq: PDII) today announced it will report financial results for its 2015 second quarter ended June 30, 2015, on Thursday, August 13, 2015, after the close of the U.S. financial markets.
PDII: 0.53 (-0.02)
Aetna Publishes Favorable Coverage Policy for ThyGenX(TM), Interpace Diagnostics' Thyroid Mutation Panel
PR Newswire - Mon Jul 06, 12:37PM CDT
PDI, Inc. (NASDAQ: PDII) subsidiary Interpace Diagnostics announced today that effective June 2015, ThyGenX(TM),i the company's genetic mutation panel, has been approved by Aetna for assessing fine needle aspiration (FNA) samples from indeterminate thyroid nodules. Aetna's coverage decision now means that ThyGenX is considered medically necessary. Aetna covers 46 million lives and its positive coverage decision brings the total number of lives covered for ThyGenX to more than 100 million.
PDII: 0.53 (-0.02)
Interpace Diagnostics Announces New Data Supporting Use of BarreGen(TM), a Molecular Test for Predicting Risk of Progression from Barrett's Esophagus to Esophageal Cancer
PR Newswire - Mon May 18, 5:30AM CDT
PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, announced today new data demonstrating the clinical value of BarreGen(TM), a molecular diagnostic test for predicting risk of progression from Barrett's esophagus to esophageal cancer approximately three to four years before the cancer develops.
PDII: 0.53 (-0.02)
Interpace Diagnostics Presents New Data at American Association of Clinical Endocrinologists (AACE) Annual Congress Demonstrating Unsurpassed Performance of ThyraMIR(TM) in Combination with ThyGenX(TM)
PR Newswire - Thu May 14, 9:45AM CDT
PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, announced data today from two studies showing that ThyraMIR(TM), a novel microRNA gene expression classifier combined with ThyGenX(TM),1 Interpace Diagnostics' genetic mutation panel, provides physicians with a unique solution that offers an unsurpassed negative predictive value (NPV) of 94% and positive predictive value (PPV) of 74% in combination. As a result, using ThyGenX combined with ThyraMIR may potentially result in fewer unnecessary surgeries for patients with previously indeterminate thyroid nodules. These data will be presented as posters at the American Association of Clinical Endocrinologists (AACE) 24th Annual Scientific & Clinical Congress, in Nashville, Tennessee, May 13 - 17, 2015.
PDII: 0.53 (-0.02)
Onconova Therapeutics, Inc. Announces Appointment of Jack E. Stover to Board of Directors
GlobeNewswire - Mon May 23, 7:01AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Jack E. Stover has been appointed to its Board of Directors.
ONTX: 6.28 (-0.59), IDXG: 0.34 (+0.02), PDII: 0.53 (-0.02)
PDI Completes Sale of Its Commercial Services Business to Publicis Healthcare Communications Group
PR Newswire - Tue Dec 22, 12:07PM CST
PDI, Inc. (Nasdaq: PDII) announced the closing of the definitive asset purchase agreement under which Publicis Healthcare Communications Group has acquired PDI's Commercial Services business (CSO) for the initial upfront cash payment of $25.5 million. The total gross cash proceeds are approximately $28.5 million, which includes the upfront cash payment as well as a closing working capital payment. The agreement was previously announced on November 2nd, 2015 and on December 22, 2015 the transaction was approved by a majority of the PDI stockholders. Today, PDI changed its corporate name to Interpace Diagnostics Group (Interpace), Inc. and it will begin trading under the trading symbol IDXG on NASDAQ on December 23, 2015. The Company is using the proceeds from the transaction to pay off its existing senior commercial debt and for ongoing working capital to drive the growth of its molecular diagnostics operations.
PDII: 0.53 (-0.02)
PDI, Inc. Implements Leadership Transition
PR Newswire - Tue Dec 22, 5:00AM CST
PDI, Inc.(Nasdaq: PDII) today reported that as the Company transitions to focusing solely on its molecular diagnostics operations, Nancy Lurker has resigned as President, CEO and a member of the Company's board of directors effective immediately upon the expected closing of the proposed sale of the Company's Commercial Services Business. She has been succeeded on an interim basis by Jack E. Stover, previously Chairman of the Company's Audit Committee, while a search for a permanent chief executive officer has been initiated.
PDII: 0.53 (-0.02)
PDI, Inc. Implements Broad Based Efficiencies To Position Interpace Diagnostics For Long Term Growth
PR Newswire - Mon Dec 07, 8:12AM CST
PDI, Inc. (NASDAQ: PDII) implemented a broad based program to maximize efficiencies as the Company expects to close its sale of the CSO business by the end of 2015 and focus its resources on growing its Interpace Diagnostics business. As previously disclosed, upon closing of the proposed sale of the CSO business, PDI will change its name to Interpace Diagnostics Group, Inc.
PDII: 0.53 (-0.02)
PDI, Inc. Sets Special Stockholder Meeting Date of December 22, 2015 to Vote on Sale of Commercial Services (CSO) Business to Publicis Groupe
PR Newswire - Mon Nov 23, 3:20PM CST
PDI, Inc. (Nasdaq: PDII) today reported that its Board of Directors has set December 22, 2015 as the date of the special meeting of its stockholders to vote on the proposed sale of its Commercial Services business (CSO) to Publicis Healthcare Communications Group (PHCG), part of Publicis Groupe [Euronext Paris: FR0000130577, CAC40] pursuant to an asset purchase agreement entered into on October 30, 2015. The special meeting of stockholders will be held at PDI's corporate headquarters located at Morris Corporate Center One, 300 Interpace Parkway, Building A, Parsippany, NJ 07054. Stockholders of record as of November 20, 2015 are entitled to notice of and to vote at the special meeting.
PDII: 0.53 (-0.02)
Interpace Diagnostics Announces Continued Medicare Coverage for PancraGEN(TM) Pancreatic Cyst Risk Classifier Test
PR Newswire - Mon Nov 16, 5:30AM CST
PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, announced today that Novitas Solutions, Inc., the Medicare Administrative Contractor (MAC) for Interpace Diagnostics, has updated its Local Coverage Determination (LCD) for PancraGEN(TM). The PancraGEN test utilizes the PathFinderTG® platform. The original coverage issued on November 5th, 2010 provided "Coverage with Appropriateness Development," which required the Company to routinely present updated data to further validate the test's effectiveness. The new policy no longer includes this condition for coverage and is effective December 31st, 2015 and ensures continued coverage of PancraGEN for Medicare eligible patients.
PDII: 0.53 (-0.02)
PDI Reports 2015 Third Quarter and Nine Months Financial Results
PR Newswire - Thu Nov 12, 3:01PM CST
PDI, Inc. (NASDAQ: PDII) today reported financial and operational results for the third quarter and nine months ended September 30, 2015.
PDII: 0.53 (-0.02)
PDI Inc. to Report 2015 Third Quarter Financial Results
PR Newswire - Thu Nov 05, 12:04PM CST
PDI, Inc. (Nasdaq: PDII) today announced it will report financial results for its 2015 third quarter ended September 30, 2015, on Thursday, November 12, 2015, after the close of the U.S. financial markets.
PDII: 0.53 (-0.02)
PDI Enters Definitive Agreement to Sell Its Commercial Services Business to Publicis Healthcare Communications Group
PR Newswire - Mon Nov 02, 1:00AM CST
PDI, Inc. (Nasdaq: PDII) and Publicis Healthcare Communications Group (PHCG), part of Publicis Groupe [Euronext Paris: FR0000130577, CAC40], have entered into a definitive asset purchase agreement under which PHCG will acquire PDI's Commercial Services business (CSO) for an initial cash payment at closing of up to approximately $33 million, $7 million of which is contingent upon securing certain CSO client commitments, plus an earnout payment based upon 2016 CSO revenue. While there are no assurances that any earnout payment will be achieved, PDI expects the earnout payment to range from $5 million to $15 million if certain CSO client commitments are obtained. If earned, the earnout payment will be payable in April 2017. This transaction, which has been unanimously approved by the board of directors of both companies, is subject to PDI's stockholder approval and customary closing conditions. Stockholders representing approximately 46% percent of PDI's outstanding shares have agreed, subject to certain conditions, to vote in favor of the transaction.
PDII: 0.53 (-0.02)
Interpace Diagnostics Announces New Data Further Validating the Power of the Combination of its Molecular Diagnostic Thyroid Tests ThyGenX® and ThyraMIR(TM)
PR Newswire - Wed Oct 21, 8:01AM CDT
PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, announced new data presented at the 15th International Thyroid Congress and 85th Annual Meeting of the American Thyroid Association (ITC/ATA) this week in Lake Buena Vista, Florida (www.ITC2015.thyroid.org) demonstrating that combination testing by ThyGenX®, oncogene panel, and ThyraMIR(TM), microRNA classifier, has been analytically validated on fixed nodule specimens including Formalin Fixed Paraffin Embedded (FFPE) samples, cytology slides and Thin Prep slides, in addition to the current molecular analysis of fine needle aspirations (FNAs). The ability to analyze fixed thyroid samples now allows for molecular evaluation of older archived samples. An additional benefit is that this expanded menu of molecular testing on cytology slides and Thin Prep sample types can potentially eliminate the need for a second needle pass during patient biopsy.
PDII: 0.53 (-0.02)
Interpace Diagnostics Announces New Analyses Showing Positive Impact of PancraGEN(TM) in the Clinical Management of Pancreatic Cysts
PR Newswire - Mon Oct 19, 7:00AM CDT
PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, announced data that were presented in two posters during the American College of Gastroenterology (ACG) Annual Scientific Meeting and Postgraduate Course, October 16-21, 2015, Honolulu, Hawaii. The data presented demonstrated that PancraGEN(TM) can improve the detection of malignant or highly aggressive pancreatic cysts over current guideline criteria in patient management.
PDII: 0.53 (-0.02)
PDI Loss Narrower than Expected in Q2, Revenues Surpass
Zacks Equity Research - Zacks Investment Research - Fri Aug 14, 9:10AM CDT
PDI, Inc. (PDII) incurred operating loss of 44 cents in the second quarter of 2015, narrower than the Zacks Consensus Estimate of loss of 46 cents.
SFUN: 4.79 (+0.06), PDII: 0.53 (-0.02), CORE: 89.50 (-2.50), CATM: 40.27 (-0.85)
Interpace Diagnostics Announces Additional Coverage in Top Managed Care Health Plans for Their Thyroid and Pancreas Molecular Diagnostic Tests
PR Newswire - Thu Aug 13, 3:27PM CDT
PDI, Inc. (NASDAQ: PDII) subsidiary Interpace Diagnostics announced today that both the ThyGenX(TM) Thyroid Oncogene Panel and ThyraMIR(TM) Thyroid miRNA Classifier, its molecular diagnostic tests for indeterminate thyroid nodules, are now covered by one of the largest independent Blue Cross Blue Shield plans that insures 3.3 million lives. This medical policy update, covering both ThyGenX and ThyraMIR, represents the first large commercial plan to cover ThyraMIR, a novel microRNA gene expression classifier launched earlier this year. Furthermore, it follows the recent announcement of coverage by Aetna for ThyGenX, Interpace Diagnostics' genetic mutation panel used to improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis of thyroid cancer. The combination of all plans, including Medicare coverage of ThyGenX, represents a total of 80 million covered lives for Interpace Diagnostics' molecular thyroid diagnostic tests.
PDII: 0.53 (-0.02)
PDI Reports 2015 Second Quarter and Six Months Financial Results
PR Newswire - Thu Aug 13, 3:01PM CDT
PDI, Inc. (NASDAQ: PDII) today reported financial and operational results for the second quarter and six months ended June 30, 2015.
PDII: 0.53 (-0.02)
PDI Inc. to Report 2015 Second Quarter Financial Results
PR Newswire - Tue Aug 04, 6:30AM CDT
PDI, Inc. (Nasdaq: PDII) today announced it will report financial results for its 2015 second quarter ended June 30, 2015, on Thursday, August 13, 2015, after the close of the U.S. financial markets.
PDII: 0.53 (-0.02)
Aetna Publishes Favorable Coverage Policy for ThyGenX(TM), Interpace Diagnostics' Thyroid Mutation Panel
PR Newswire - Mon Jul 06, 12:37PM CDT
PDI, Inc. (NASDAQ: PDII) subsidiary Interpace Diagnostics announced today that effective June 2015, ThyGenX(TM),i the company's genetic mutation panel, has been approved by Aetna for assessing fine needle aspiration (FNA) samples from indeterminate thyroid nodules. Aetna's coverage decision now means that ThyGenX is considered medically necessary. Aetna covers 46 million lives and its positive coverage decision brings the total number of lives covered for ThyGenX to more than 100 million.
PDII: 0.53 (-0.02)
Interpace Diagnostics Announces New Data Supporting Use of BarreGen(TM), a Molecular Test for Predicting Risk of Progression from Barrett's Esophagus to Esophageal Cancer
PR Newswire - Mon May 18, 5:30AM CDT
PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, announced today new data demonstrating the clinical value of BarreGen(TM), a molecular diagnostic test for predicting risk of progression from Barrett's esophagus to esophageal cancer approximately three to four years before the cancer develops.
PDII: 0.53 (-0.02)
Interpace Diagnostics Presents New Data at American Association of Clinical Endocrinologists (AACE) Annual Congress Demonstrating Unsurpassed Performance of ThyraMIR(TM) in Combination with ThyGenX(TM)
PR Newswire - Thu May 14, 9:45AM CDT
PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, announced data today from two studies showing that ThyraMIR(TM), a novel microRNA gene expression classifier combined with ThyGenX(TM),1 Interpace Diagnostics' genetic mutation panel, provides physicians with a unique solution that offers an unsurpassed negative predictive value (NPV) of 94% and positive predictive value (PPV) of 74% in combination. As a result, using ThyGenX combined with ThyraMIR may potentially result in fewer unnecessary surgeries for patients with previously indeterminate thyroid nodules. These data will be presented as posters at the American Association of Clinical Endocrinologists (AACE) 24th Annual Scientific & Clinical Congress, in Nashville, Tennessee, May 13 - 17, 2015.
PDII: 0.53 (-0.02)
